Sanofi and Blackstone Life Science collaborate to advance multiple myeloma treatment

pharmafile | March 15, 2022 | News story | Manufacturing and Production  

Sanofi and Blackstone announced a strategic, risk-sharing €300 million collaboration, to advance innovative treatment for multiple myeloma.

This funding will be used to accelerate the global pivotal studies and the clinical development programme for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa, to treat patients with multiple myeloma (MM).

To deliver the Sarclisa subcutaneous formulation, Sanofi has partnered with drug delivery technology innovator company Enable Injections Inc to advance the development of a subcutaneous delivery for Sarclisa with the goal of offering a unique patient-centric treatment experience.

John Reed, MD, PhD, Global Head of Research and Development for Sanofi, commented: “The collaboration with Blackstone will accelerate our ability to offer patients a subcutaneous anti-CD38 antibody therapy that we believe will be innovative and more convenient. We are committed to building an industry-leading, sustainable pipeline with a steady stream of new therapies that have the potential to transform the practice of medicine.”

Nicholas Galakatos, PhD, Global Head of Blackstone Life Sciences, added: “We are excited to collaborate with Sanofi’s experienced development team to advance a subcutaneous dosage form for Sarclisa forpatients. Our investment demonstrates Blackstone’s commitment and ability to provide innovative sources of financing to the world’s leading pharmaceutical companies as we offer capital at scale and complementary expertise to help advance important medicines in critical therapeutic areas.”

Lina Adams

Related Content

No items found

Latest content